Featured Research Search Results

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone or Darolutamide (TALENT)

Clinicaltrials.gov identifier:
NCT06844383

Treatment
Phase 2 study for metastatic castration-resistant prostate cancer with an HRR mutation

ShareForCures®: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry

Clinicaltrials.gov identifier:
NCT05654246

Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer

Understanding Risk Factors for Stomach Cancer in People with Inherited Mutations

Surveys, Registries, Interviews
Online survey on stomach cancer risk for people with an inherited mutation in genes that are linked to an increased risk of certain cancers

A 5-minute Patient and Caregiver survey to share experiences with immunotherapy and any short-term or long-term side effects

Surveys, Registries, Interviews
This 5-minute survey allows cancer patients on immunotherapy (currently or in the past) and their caregivers to share their experiences, including their side effects and whether they were resolved or not.

Evaluating the Safety of Nipple Sparing Mastectomy in Women With a High Risk for Breast Cancer

Clinicaltrials.gov identifier:
NCT06888388

Prevention
Study for people considering double mastectomy to reduce breast cancer risk

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Clinicaltrials.gov identifier:
NCT06195306

Prevention
Phase 2 study for overweight postmenopausal women at increased risk for breast cancer

A New Targeted Therapy CX‑5461 to Treat Advanced Breast, Ovarian, Pancreatic or Prostate Cancer with Inherited or Tumor Mutations

Clinicaltrials.gov identifier:
NCT04890613

Treatment
Phase 1 treatment study for advanced or metastatic breast, ovarian, pancreatic or prostate cancer

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

Clinicaltrials.gov identifier:
NCT06380751

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer

Clinicaltrials.gov identifier:
NCT06748222

Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib

Clinicaltrials.gov identifier:
NCT06488378

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT06401421

Treatment
Biomarker study for people with early-stage breast cancer

Pancreatic Cancer Screening Study (CAPS5)

Clinicaltrials.gov identifier:
NCT02000089

Prevention
Screening study for people at high risk for pancreatic cancer

Registry for People at Increased Risk for Pancreatic Cancer

Clinicaltrials.gov identifier:
NCT06151223

Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

Clinicaltrials.gov identifier:
NCT05281471

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

Understanding the Emotional and Social Experiences of Individuals Diagnosed with Ovarian Cancer

Surveys, Registries, Interviews
Survey for people diagnosed with ovarian cancer

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

Clinicaltrials.gov identifier:
NCT04472338

Prevention
Screening study for people with a mutation linked to prostate cancer risk

The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

Surveys, Registries, Interviews
Study for people who have a BRCA1, BRCA2, or PALB2 genetic mutation

Screening Study for Men at High Genetic Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT03805919

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation